Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

Avi Israel Einzig, Lynn M. Schuchter, Adri Recio, Susan Coatsworth, Roberto Rodriquez, Peter H. Wiernik

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg m-2 administered intravenously over 1 hour every 21 days. Patients were premedicated prior to each course with dexamethasone and diphenhydramine. Toxicity and follow-up were provided. Objective responses were seen in two out of 35 patients evaluable for response, one complete response and one partial response. These two responses were of a duration of greater than two years. The most common toxicity was grade 4 neutropenia, which occurred in 92% of patients; 49% required hospitalization for an episode of neutropenic fever. Additional patients had reversible grade 3-4 toxicities including nausea, vomiting, diarrhea, stomatitis, arthralgias, myalgias, peripheral neuropathy and fatigue. Eighteen patients had hypersensitivity reactions, two were grade 3-4. Fluid retention, grade 1-3 was observed in seven patients. Alopecia occurred in most patients. Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be considered in multidrug combination programs.

Original languageEnglish (US)
Pages (from-to)111-117
Number of pages7
JournalMedical Oncology
Volume13
Issue number2
DOIs
StatePublished - Jan 1 1996

Fingerprint

docetaxel
Melanoma
Drug Therapy
Diphenhydramine
Stomatitis
Myalgia
Alopecia
Arthralgia
Peripheral Nervous System Diseases
Neutropenia

Keywords

  • Docetaxel
  • Malignant melanoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. / Einzig, Avi Israel; Schuchter, Lynn M.; Recio, Adri; Coatsworth, Susan; Rodriquez, Roberto; Wiernik, Peter H.

In: Medical Oncology, Vol. 13, No. 2, 01.01.1996, p. 111-117.

Research output: Contribution to journalArticle

Einzig, Avi Israel ; Schuchter, Lynn M. ; Recio, Adri ; Coatsworth, Susan ; Rodriquez, Roberto ; Wiernik, Peter H. / Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. In: Medical Oncology. 1996 ; Vol. 13, No. 2. pp. 111-117.
@article{152d9eb8ed1e480abd160c9df4346532,
title = "Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy",
abstract = "A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg m-2 administered intravenously over 1 hour every 21 days. Patients were premedicated prior to each course with dexamethasone and diphenhydramine. Toxicity and follow-up were provided. Objective responses were seen in two out of 35 patients evaluable for response, one complete response and one partial response. These two responses were of a duration of greater than two years. The most common toxicity was grade 4 neutropenia, which occurred in 92{\%} of patients; 49{\%} required hospitalization for an episode of neutropenic fever. Additional patients had reversible grade 3-4 toxicities including nausea, vomiting, diarrhea, stomatitis, arthralgias, myalgias, peripheral neuropathy and fatigue. Eighteen patients had hypersensitivity reactions, two were grade 3-4. Fluid retention, grade 1-3 was observed in seven patients. Alopecia occurred in most patients. Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be considered in multidrug combination programs.",
keywords = "Docetaxel, Malignant melanoma",
author = "Einzig, {Avi Israel} and Schuchter, {Lynn M.} and Adri Recio and Susan Coatsworth and Roberto Rodriquez and Wiernik, {Peter H.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1007/BF02993861",
language = "English (US)",
volume = "13",
pages = "111--117",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

AU - Einzig, Avi Israel

AU - Schuchter, Lynn M.

AU - Recio, Adri

AU - Coatsworth, Susan

AU - Rodriquez, Roberto

AU - Wiernik, Peter H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg m-2 administered intravenously over 1 hour every 21 days. Patients were premedicated prior to each course with dexamethasone and diphenhydramine. Toxicity and follow-up were provided. Objective responses were seen in two out of 35 patients evaluable for response, one complete response and one partial response. These two responses were of a duration of greater than two years. The most common toxicity was grade 4 neutropenia, which occurred in 92% of patients; 49% required hospitalization for an episode of neutropenic fever. Additional patients had reversible grade 3-4 toxicities including nausea, vomiting, diarrhea, stomatitis, arthralgias, myalgias, peripheral neuropathy and fatigue. Eighteen patients had hypersensitivity reactions, two were grade 3-4. Fluid retention, grade 1-3 was observed in seven patients. Alopecia occurred in most patients. Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be considered in multidrug combination programs.

AB - A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg m-2 administered intravenously over 1 hour every 21 days. Patients were premedicated prior to each course with dexamethasone and diphenhydramine. Toxicity and follow-up were provided. Objective responses were seen in two out of 35 patients evaluable for response, one complete response and one partial response. These two responses were of a duration of greater than two years. The most common toxicity was grade 4 neutropenia, which occurred in 92% of patients; 49% required hospitalization for an episode of neutropenic fever. Additional patients had reversible grade 3-4 toxicities including nausea, vomiting, diarrhea, stomatitis, arthralgias, myalgias, peripheral neuropathy and fatigue. Eighteen patients had hypersensitivity reactions, two were grade 3-4. Fluid retention, grade 1-3 was observed in seven patients. Alopecia occurred in most patients. Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be considered in multidrug combination programs.

KW - Docetaxel

KW - Malignant melanoma

UR - http://www.scopus.com/inward/record.url?scp=0030468023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030468023&partnerID=8YFLogxK

U2 - 10.1007/BF02993861

DO - 10.1007/BF02993861

M3 - Article

C2 - 9013474

AN - SCOPUS:0030468023

VL - 13

SP - 111

EP - 117

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 2

ER -